Advertisement Walvax adopts Medidata's technology platform for pediatric vaccine program in China - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Walvax adopts Medidata’s technology platform for pediatric vaccine program in China

Walvax Biotechnology has selected Medidata's cloud-based technology platform to advance pediatric vaccine program in China.

Medidata Clinical Cloud platform will enhance data management capabilities and drive biomedical innovation in the development of a pneumococcal conjugate vaccine for infants.

Walvax is using Medidata Rave technology for electronic data capture and management to optimize its novel research implementation on a vaccine for pneumococcal conjugate (PCV13).

Training available via Medidata’s professional services offering is also being used to accelerate study execution and meet trial timelines.

Walvax vice president Yi Zhang said: "Pneumococcal infections — including pneumonia, blood infections and meningitis — can be extremely difficult to treat, making prevention through vaccination a critical component of patient care.

"We’re pleased to be using Medidata’s robust, globally-validated technology to bring greater speed and operational efficiencies to our pneumococcal conjugate vaccine trials, ultimately leading to a safe and effective way to ensure young children are protected from the devastating effects of pneumococcal diseases."

Medidata Asia-Pacific managing director Takeru Yamamoto said: "Medidata’s cloud-based platform is designed to bring efficiencies to clinical trials of all sizes and therapeutics areas.

"We’re proud to be collaborating with Walvax as the organization advances pneumococcal conjugate vaccine research in China, resulting in better preventative treatment for young people around the world."